EBR Systems
Develops devices for the treatment of cardiac arrhythmias.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | AUD20.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 1106 % | 215 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (3600 %) | (321 %) | (91 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (3969 %) | (346 %) | (96 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
EBR Systems, Inc. specializes in developing advanced wireless cardiac pacing systems aimed at improving the treatment of heart failure. The company operates in the medical device market, focusing on Cardiac Resynchronization Therapy (CRT) for patients who require synchronized heart chamber pumping to alleviate heart failure symptoms. EBR Systems' core product, the WiSE CRT System, delivers pacing stimulation directly to the inside of the left ventricle without the need for a wire lead, offering a tailored therapy solution that meets individual patient needs. This innovative approach not only enhances treatment outcomes but also reduces complications associated with traditional wired systems.
The company primarily serves healthcare providers and patients suffering from heart failure, offering a cutting-edge solution that addresses the limitations of existing CRT technologies. EBR Systems generates revenue through the sale of its WiSE CRT System to hospitals and medical institutions, leveraging its strong team with extensive experience in medical device development and commercialization.
Keywords: wireless cardiac pacing, heart failure, CRT, medical device, left ventricle stimulation, tailored therapy, healthcare providers, innovative technology, reduced complications, patient-specific solutions.